Zeltiq CoolSculpting Elite 2020 cryolipolysis body contouring system

For Sale Zeltiq Coolsculpting Elite 2020

$21,000.00

CoolSculpting Elite is a controlled-cooling cryolipolysis system from ZELTIQ (Allergan Aesthetics), engineered to reduce stubborn subcutaneous fat without surgery or downtime. The 2020 generation introduces dual independently operated applicators with a redesigned C-shaped cup, giving up to 18% more cooling surface contact than earlier CoolSculpting models and allowing two treatment areas to be addressed simultaneously.

During treatment, gentle vacuum pressure draws tissue into the applicator, which then cools it to approximately -11°C to -13°C, triggering apoptosis (natural cell death) in fat cells while leaving the skin and surrounding tissue unaffected. The built-in Freeze Detect safety system continuously monitors heat extraction at the tissue surface to help protect against cold injury throughout each cycle.

Clinically, CoolSculpting Elite is indicated for non-invasive fat reduction in areas such as the abdomen, flanks, thighs, upper arms, and submental (under-chin) region, with most patients seeing a visible reduction of roughly 20–25% in treated fat over the following weeks as the body naturally clears the disrupted cells.

MedicalZenith supplies CoolSculpting Elite systems to aesthetic clinics and hospitals across Indonesia, complete with installation support and consumables sourcing. Contact our team for current availability, financing options, and full technical documentation.

This is frequently paired with Cynosure SculpSure Body Contour Laser and Alma vShape Ultra System for a more complete setup.

Brand / Manufacturer
ZELTIQ (Allergan Aesthetics / AbbVie)
Model / Year
CoolSculpting Elite
2020
Technology
Controlled-cooling cryolipolysis
Applicator Configuration
Dual independent applicators
C-shaped contoured cups
Cooling Temperature Range
Approx. -11°C to -13°C
Cooling Surface Coverage
Up to 18% larger than legacy CoolSculpting applicators
Safety System
Freeze Detect real-time tissue monitoring
Primary Indications
Non-invasive fat reduction: abdomen
flanks
thighs
arms
submental area
Expected Fat Reduction
Approximately 20–25% in treated area per session
Regulatory Status
FDA-cleared